These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 29133549)
1. Pharmacokinetics and Exposure-Response Analysis of RG7667, a Combination of Two Anticytomegalovirus Monoclonal Antibodies, in a Phase 2a Randomized Trial To Prevent Cytomegalovirus Infection in High-Risk Kidney Transplant Recipients. Deng R; Wang Y; Maia M; Burgess T; McBride JM; Liao XC; Tavel JA; Hanley WD Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133549 [TBL] [Abstract][Full Text] [Related]
2. Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of RG7667, a Combination Monoclonal Antibody, for Prevention of Cytomegalovirus Infection in High-Risk Kidney Transplant Recipients. Ishida JH; Patel A; Mehta AK; Gatault P; McBride JM; Burgess T; Derby MA; Snydman DR; Emu B; Feierbach B; Fouts AE; Maia M; Deng R; Rosenberger CM; Gennaro LA; Striano NS; Liao XC; Tavel JA Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872061 [TBL] [Abstract][Full Text] [Related]
3. Phase 1 Randomized, Double-Blind, Placebo-Controlled Study of RG7667, an Anticytomegalovirus Combination Monoclonal Antibody Therapy, in Healthy Adults. Ishida JH; Burgess T; Derby MA; Brown PA; Maia M; Deng R; Emu B; Feierbach B; Fouts AE; Liao XC; Tavel JA Antimicrob Agents Chemother; 2015 Aug; 59(8):4919-29. PubMed ID: 26055360 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of cytomegalovirus (CMV)-specific T cell immune reconstitution revealed that baseline antiviral immunity, prophylaxis, or preemptive therapy but not antithymocyte globulin treatment contribute to CMV-specific T cell reconstitution in kidney transplant recipients. Abate D; Saldan A; Fiscon M; Cofano S; Paciolla A; Furian L; Ekser B; Biasolo MA; Cusinato R; Mengoli C; Bonfante L; Rossi B; Rigotti P; Sgarabotto D; Barzon L; Palù G J Infect Dis; 2010 Aug; 202(4):585-94. PubMed ID: 20594105 [TBL] [Abstract][Full Text] [Related]
5. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease]. Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888 [TBL] [Abstract][Full Text] [Related]
6. Comparison of Preemptive Therapy and Antiviral Prophylaxis for Prevention of Cytomegalovirus in Seropositive Liver Transplant Recipients. Liu AW; Jutivorakool K; Fisher CE; Rakita RM; Reyes JD; Bhattacharya RB; Jerome KR; Limaye AP Transplantation; 2018 Apr; 102(4):632-639. PubMed ID: 29215460 [TBL] [Abstract][Full Text] [Related]
7. Cytomegalovirus viraemia and mortality in renal transplant recipients in the era of antiviral prophylaxis. Lessons from the western Australian experience. Selvey LA; Lim WH; Boan P; Swaminathan R; Slimings C; Harrison AE; Chakera A BMC Infect Dis; 2017 Jul; 17(1):501. PubMed ID: 28716027 [TBL] [Abstract][Full Text] [Related]
8. Impact of a preemptive strategy after 3 months of valganciclovir cytomegalovirus prophylaxis in kidney transplant recipients. Boillat Blanco N; Pascual M; Venetz JP; Nseir G; Meylan PR; Manuel O Transplantation; 2011 Jan; 91(2):251-5. PubMed ID: 21099744 [TBL] [Abstract][Full Text] [Related]
9. Preemptive anti-cytomegalovirus therapy in high-risk (donor-positive, recipient-negative cytomegalovirus serostatus) kidney transplant recipients. Hasegawa J; Hatakeyama S; Wakai S; Omoto K; Okumi M; Tanabe K; Mieno M; Shirakawa H Int J Infect Dis; 2017 Dec; 65():50-56. PubMed ID: 28986314 [TBL] [Abstract][Full Text] [Related]
10. Prolonged Low-Dose Prophylaxis With Valganciclovir in Cytomegalovirus-Negative Recipients of Kidney Transplants From Cytomegalovirus-Positive Donors Allows Seroconversion and Prevents Cytomegalovirus Disease. Halleck F; Khadzhynov D; Schrezenmeier E; Lehner L; Budde K; Staeck O Transplant Proc; 2017 Dec; 49(10):2280-2284. PubMed ID: 29198661 [TBL] [Abstract][Full Text] [Related]
11. Cytomegalovirus load at treatment initiation is predictive of time to resolution of viremia and duration of therapy in hematopoietic cell transplant recipients. Tan SK; Waggoner JJ; Pinsky BA J Clin Virol; 2015 Aug; 69():179-83. PubMed ID: 26209403 [TBL] [Abstract][Full Text] [Related]
12. Human monoclonal antibodies neutralizing cytomegalovirus (CMV) for prophylaxis of CMV disease: report of a phase I trial in bone marrow transplant recipients. Aulitzky WE; Schulz TF; Tilg H; Niederwieser D; Larcher K; Ostberg L; Scriba M; Martindale J; Stern AC; Grass P J Infect Dis; 1991 Jun; 163(6):1344-7. PubMed ID: 1645384 [TBL] [Abstract][Full Text] [Related]
13. Poxvirus Vectored Cytomegalovirus Vaccine to Prevent Cytomegalovirus Viremia in Transplant Recipients: A Phase 2, Randomized Clinical Trial. Aldoss I; La Rosa C; Baden LR; Longmate J; Ariza-Heredia EJ; Rida WN; Lingaraju CR; Zhou Q; Martinez J; Kaltcheva T; Dagis A; Hardwick N; Issa NC; Farol L; Nademanee A; Al Malki MM; Forman S; Nakamura R; Diamond DJ; Ann Intern Med; 2020 Mar; 172(5):306-316. PubMed ID: 32040960 [TBL] [Abstract][Full Text] [Related]
14. Preemptive therapy is not adequate for prevention of cytomegalovirus disease in pancreas-kidney transplant recipients. López-Medrano F; Rueda B; Lizasoain M; Juan RS; Folgueira D; Andrés A; Morales JM; Jiménez C; Meneu JC; Aguado JM Transpl Infect Dis; 2009 Oct; 11(5):400-4. PubMed ID: 19570139 [TBL] [Abstract][Full Text] [Related]
15. Clinical course of cytomegalovirus (CMV) viremia with and without ganciclovir treatment in CMV-seropositive kidney transplant recipients. Longitudinal follow-up of CMV pp65 antigenemia assay. Yang CW; Kim YO; Kim YS; Kim SY; Moon IS; Ahn HJ; Koh YB; Bang BK Am J Nephrol; 1998; 18(5):373-8. PubMed ID: 9730559 [TBL] [Abstract][Full Text] [Related]
16. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation. Becker BN; Becker YT; Leverson GE; Simmons WD; Sollinger HW; Pirsch JD Am J Kidney Dis; 2002 May; 39(5):1088-95. PubMed ID: 11979354 [TBL] [Abstract][Full Text] [Related]
17. Prophylaxis versus pre-emptive treatment for prevention of cytomegalovirus infection in CMV-seropositive orthotopic liver-transplant recipients. Mengelle C; Rostaing L; Weclawiak H; Rossignol C; Kamar N; Izopet J J Med Virol; 2015 May; 87(5):836-44. PubMed ID: 25655981 [TBL] [Abstract][Full Text] [Related]
18. A randomized, phase 2 study of ASP0113, a DNA-based vaccine, for the prevention of CMV in CMV-seronegative kidney transplant recipients receiving a kidney from a CMV-seropositive donor. Vincenti F; Budde K; Merville P; Shihab F; Ram Peddi V; Shah M; Wyburn K; Cassuto-Viguier E; Weidemann A; Lee M; Flegel T; Erdman J; Wang X; Lademacher C Am J Transplant; 2018 Dec; 18(12):2945-2954. PubMed ID: 29745007 [TBL] [Abstract][Full Text] [Related]
19. Enzyme-Linked Immunospot Assay as a Complementary Method to Assess and Monitor Cytomegalovirus Infection in Kidney Transplant Recipients on Pre-emptive Antiviral Therapy: A Single-Center Experience. Favi E; Santangelo R; Iesari S; Morandi M; Marcovecchio GE; Trecarichi EM; Salerno MP; Ferraresso M; Citterio F; Romagnoli J Transplant Proc; 2017 Oct; 49(8):1766-1772. PubMed ID: 28923622 [TBL] [Abstract][Full Text] [Related]
20. Acquisition of Antibody Against Cytomegalovirus After Kidney Transplantation in Seronegative Recipients. Ishikawa S; Tasaki M; Saito K; Nakagawa Y; Ikeda M; Takahashi K; Tomita Y Transplant Proc; 2023 May; 55(4):809-814. PubMed ID: 37061354 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]